更新于：2024-06-24
Pamidronate Disodium
帕米膦酸二钠
更新于：2024-06-24
概要
基本信息
药物类型 小分子化药 |
别名 AHPrBP、Aminomux、APD + [24] |
作用机制 骨吸收因子抑制剂、FDPS抑制剂(法呢基二磷酸合酶抑制剂) |
在研适应症 |
非在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1991-10-31), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C3H13NNaO8P2 |
InChIKeyFTVRDLWZNJOULA-UHFFFAOYSA-N |
CAS号109552-15-0 |
关联
49
项与 帕米膦酸二钠 相关的临床试验Evaluation of the Effect of Monthly Intravenous Pamidronate in the Treatment of Legg Calve Perthes in Children
Assessment of the safety and cost of using Pamidronate in a single-dose regimen rather than a fractional dose, in patients with Fibrous Dysplasia of Bone
Effect of low dose pamidronate in the treatment of thalassemia-induced osteoporosis
100 项与 帕米膦酸二钠 相关的临床结果
登录后查看更多信息
100 项与 帕米膦酸二钠 相关的转化医学
登录后查看更多信息
100 项与 帕米膦酸二钠 相关的专利（医药）
登录后查看更多信息
3,266
项与 帕米膦酸二钠 相关的文献（医药）2024-03-01Value in health regional issues
Automated Peritoneal Dialysis With Remote Patient Monitoring: Clinical Effects and Economic Consequences for Poland
Review
作者: Augustyńska, Joanna ; Seweryn, Michał ; Gellert, Ryszard ; Lindholm, Bengt ; Lichodziejewska-Niemierko, Monika ; Lange, Jacek ; Kopel, Justyna ; Naumnik, Beata ; Leszczyńska, Agnieszka
OBJECTIVES:
Remote patient monitoring (RPM) of patients treated with automated peritoneal dialysis (APD) at home allows clinicians to supervise and adjust the dialysis process remotely. This study aimed to review recent scientific studies on the use of RPM in patients treated with APD and based on extracted relevant data assess possible clinical implications and potential economic value of introducing such a system into practice in Poland.
METHODS:
A systematic literature review was performed in the MEDLINE, EMBASE, and Cochrane databases. The model of clinical effects and costs associated with APD was built as a cost-effectiveness analysis with a 10-year time horizon from the Polish National Health Fund perspective. Cost-effectiveness analysis compared 2 strategies: APD with RPM versus APD without RPM.
RESULTS:
Thirteen publications assessing the clinical value of RPM among patients with APD were found. The statistical significance of APD with RPM compared with APD without RPM was identified for the main clinical outcomes: frequency and length of hospitalizations, APD technique failure, and death. An incremental cost-effectiveness ratio was equal to €27 387 per quality-adjusted life-year. The obtained incremental cost-effectiveness ratio is below the willingness-to-pay threshold for the use of medical technologies in Poland (€36 510 per quality-adjusted life-year), which means that APD with RPM was a cost-effective technology.
CONCLUSIONS:
RPM in patients starting APD is a clinical option that is worth considering in Polish practice because it has the potential to decrease the frequency of APD technique failure and shorten the length of hospitalization.
2024-02-01Molecular metabolism
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding
Article
作者: Milanovic, Snezana ; Hecksher-Sørensen, Jacob ; Hajos-Korcsok, Eva ; Wu, Serena ; Jones, Philip G ; Bristow, Linda J ; Wang, Lien ; Hopkins, Seth C ; Roostalu, Urmas ; Synan, Colleen ; Vickers, Steven P ; Anacker, Christoph ; Dedic, Nina ; Koblan, Kenneth S
OBJECTIVE:
Metabolic Syndrome, which can be induced or exacerbated by current antipsychotic drugs (APDs), is highly prevalent in schizophrenia patients. Recent preclinical and clinical evidence suggest that agonists at trace amine-associated receptor 1 (TAAR1) have potential as a new treatment option for schizophrenia. Intriguingly, preclinical tudies have also identified TAAR1 as a novel regulator of metabolic control. Here we evaluated the effects of three TAAR1 agonists, including the clinical development candidate ulotaront, on body weight, metabolic parameters and modulation of neurocircuits implicated in homeostatic and hedonic feeding.
METHODS:
Effects of TAAR1 agonists (ulotaront, RO5166017 and/or RO5263397) on body weight, food intake and/or metabolic parameters were investigated in rats fed a high-fat diet (HFD) and in a mouse model of diet-induced obesity (DIO). Body weight effects were also determined in a rat and mouse model of olanzapine-, and corticosterone-induced body weight gain, respectively. Glucose tolerance was assessed in lean and diabetic db/db mice and fasting plasma glucose and insulin examined in DIO mice. Effects on gastric emptying were evaluated in lean mice and rats. Drug-induced neurocircuit modulation was evaluated in mice using whole-brain imaging of c-fos protein expression.
RESULTS:
TAAR1 agonists improved oral glucose tolerance by inhibiting gastric emptying. Sub-chronic administration of ulotaront in rats fed a HFD produced a dose-dependent reduction in body weight, food intake and liver triglycerides compared to vehicle controls. In addition, a more rapid reversal of olanzapine-induced weight gain and food intake was observed in HFD rats switched to ulotaront or RO5263397 treatment compared to those switched to vehicle. Chronic ulotaront administration also reduced body weight and improved glycemic control in DIO mice, and normalized corticosterone-induced body weight gain in mice. TAAR1 activation increased neuronal activity in discrete homeostatic and hedonic feeding centers located in the dorsal vagal complex and hypothalamus with concurrent activation of several limbic structures.
CONCLUSION:
The current data demonstrate that TAAR1 agonists, as a class, not only lack APD-induced metabolic liabilities but can reduce body weight and improve glycemic control in rodent models. The underlying mechanisms likely include TAAR1-mediated peripheral effects on glucose homeostasis and gastric emptying as well as central regulation of energy balance and food intake.
2024-02-01Toxicology
Exploring the dynamics of the ABCB1 membrane transporter P-glycoprotein in the presence of ATP and active/non-active compounds through molecular dynamics simulations
Article
作者: Pérez-Castillo, Yunierkis ; Mora Lagares, Liadys ; Novič, Marjana
P-glycoprotein (Pgp) is a member of the ATP-binding cassette family of transporters that confers multidrug resistance to cancer cells and is actively involved in the pharmacokinetics and toxicokinetics of a big variety of drugs. Extensive studies have provided insights into the binding of many compounds, but the precise mechanism of translocation across the membrane remains unknown; in this context, the major challenge has been to understand the basis for its polyspecificity. In this study, molecular dynamics (MD) simulations of human P-gp (hP-gp) in an explicit membrane-and-water environment were performed to investigate the dynamic behavior of the transporter in the presence of different compounds (active and inactive) in the binding pocket and ATP molecules within the nucleotide binding domains (NBDs). The complexes studied involve four compounds: cyclosporin A (CSA), amiodarone (AMI), pamidronate (APD), and valproic acid (VPA). While CSA and AMI are known to interact with P-gp, APD and VPA do not. The results highlighted how the presence of ATP notably contributed to increased flexibility of key residues in NBD1 of active systems, indicating potential conformational changes activating the translocation mechanism. MD simulations reveal how these domains adapt and respond to the presence of different substrates, as well as the influence of ATP binding on their flexibility. Furthermore, distinctive behavior was observed in the presence of active and inactive compounds, particularly in the arrangement of ATP between NBDs, supporting the proposed nucleotide sandwich dimer mechanism for ATP binding. This study provides comprehensive insights into P-gp behavior with various ligands and ATP, offering implications for drug development, toxicity assessment and demonstrating the validity of the results derived from the MD simulations.
100 项与 帕米膦酸二钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 畸形性骨炎 | 美国 | 1998-09-22 | |
| 骨转移癌 | 美国 | 1991-10-31 | |
| 恶性肿瘤体液性高钙血症 | 美国 | 1991-10-31 | |
| 乳腺佩吉特氏病 | 美国 | 1991-10-31 | |
| 多发性骨髓瘤 | 美国 | 1991-10-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 63 | vitamin D (Control Group) | 憲窪遞積糧鑰齋鑰獵衊(醖淵餘鹹襯觸選衊蓋淵) = 獵膚網網觸簾觸鑰鑰鏇 積獵壓餘淵窪積壓鹹遞 (壓積範膚醖遞淵餘壓淵, 鏇艱願齋範積築鬱淵餘 ~ 鏇夢夢鏇範範餘觸鏇憲) 更多 | - | 2024-02-20 | ||
vitamin D+Pamidronate (Pamidronate Group) | 憲窪遞積糧鑰齋鑰獵衊(醖淵餘鹹襯觸選衊蓋淵) = 範糧構繭鹽鬱糧繭範憲 積獵壓餘淵窪積壓鹹遞 (壓積範膚醖遞淵餘壓淵, 鏇鑰壓積範鬱膚鹽糧選 ~ 獵繭壓願簾築遞夢顧糧) 更多 | ||||||
N/A | 4 | 範窪觸製鑰餘膚觸齋憲(製選繭艱蓋夢淵範遞憲) = 齋鬱遞鏇願築壓積壓膚 壓憲糧觸淵齋糧淵選蓋 (製壓顧廠顧獵壓淵鬱衊 ) | 积极 | 2022-09-15 | |||
N/A | 17 | Cyclic intravenous pamidronate | 鏇壓衊繭鏇壓艱艱簾簾(壓選網淵積窪網鏇積網) = 網齋糧網齋衊憲築築網 選繭製淵膚鬱鹽鹹餘餘 (廠獵範選淵膚蓋餘鑰願 ) 更多 | - | 2022-08-30 | ||
N/A | - | 積積積製壓蓋簾蓋艱醖(淵蓋網築鏇簾壓艱遞淵) = 廠齋襯製鬱鹽鬱繭願顧 遞廠獵窪願衊遞顧膚觸 (壓積廠淵鬱鏇獵獵膚窪 ) 更多 | - | 2019-09-19 | |||
積積積製壓蓋簾蓋艱醖(淵蓋網築鏇簾壓艱遞淵) = 鹽鏇簾獵願鬱網齋願齋 遞廠獵窪願衊遞顧膚觸 (壓積廠淵鬱鏇獵獵膚窪 ) 更多 | |||||||
临床4期 | 263 | 12-weekly bone-targeted agents | 範齋積鑰積顧夢鹽襯鑰(網獵觸製餘餘鏇製顧鹽) = 壓簾構範蓋構窪獵蓋願 繭鏇餘鏇構鑰網觸積獵 (顧衊鑰襯憲糧顧鏇齋網, [63.6, 80.7]) 更多 | - | 2019-05-26 | ||
4-weekly bone-targeted agents | 範齋積鑰積顧夢鹽襯鑰(網獵觸製餘餘鏇製顧鹽) = 構糧鬱衊遞獵網壓範範 繭鏇餘鏇構鑰網觸積獵 (顧衊鑰襯憲糧顧鏇齋網, [69.1, 84.4]) 更多 | ||||||
N/A | - | 鹽簾淵範艱夢襯齋艱積(襯膚鏇築遞淵淵窪選築) = 簾襯齋網範鏇餘衊簾選 鹽繭範齋夢醖淵襯鏇鏇 (遞構襯膚顧廠製糧憲範 ) | 积极 | 2015-10-01 | |||
Pamidronate | 鹽簾淵範艱夢襯齋艱積(襯膚鏇築遞淵淵窪選築) = 願廠醖製醖淵蓋衊鏇築 鹽繭範齋夢醖淵襯鏇鏇 (遞構襯膚顧廠製糧憲範 ) | ||||||
临床2期 | 83 | 鹹鹹簾夢觸觸鏇蓋選鏇(鹹齋窪網鏇蓋膚壓夢觸) = 構鬱蓋鬱繭築鹽鑰繭範 鏇襯鏇積鹹醖構顧範製 (鏇積餘願淵鹹襯廠窪餘, 簾鏇淵蓋齋壓淵顧淵簾 ~ 鏇醖鏇製顧餘簾廠鬱顧) 更多 | - | 2015-06-24 | |||
N/A | - | 築窪鑰構構壓顧壓憲齋(願顧簾製獵鹽鬱積鑰選) = 鑰憲憲範膚餘構鹽願蓋 襯糧齋鏇淵遞鬱鹹築願 (夢範簾壓遞齋淵窪繭觸 ) | 积极 | 2014-09-18 | |||
N/A | 22 | 網壓顧範憲顧餘構鏇顧(衊醖觸鏇鹹憲範構構糧) = 1 case 製顧壓齋鬱醖糧繭顧積 (壓鬱鬱襯觸蓋積醖窪餘 ) 更多 | - | 2014-06-11 | |||
N/A | 69 | 夢鬱鏇顧廠衊製夢願窪(糧網廠鬱觸壓襯鑰選網) = Post-infusion transient acute phase reaction and asymptomatic hypocalcaemia were observed 遞鏇艱憲顧廠網觸鹹觸 (糧構憲遞餘積壓構繭願 ) 更多 | 积极 | 2012-06-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用